Sarah Glewis

9PUBLICATIONS
16CO-AUTHORS
Predictive and prognostic markersPharmacogenomicsCancer genetics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|May 21, 2026
Pre-emptive DPYD genotyping and fluoropyrimidine dose optimisation: Dose tolerance and survival in cancer patients.

|Oct 27, 2025
Cost-Effectiveness of Pre-emptive DPYD Genotyping Compared to Standard of Care Among Patients Receiving Fluoropyrimidine-Based Anti-cancer Treatment in Australia.

Sarah Glewis, Mussab Fagery, Senthil Lingaratnam

|Mar 19, 2025
Informing Implementation Strategies for Pharmacogenomics in Cancer: Development of Survey Tools for Healthcare Professionals and Consumers.

Marliese Alexander, Chiao Xin Lim, Senthil Lingaratnam

|Feb 24, 2025
Feasibility and population exposure of 5-fluorouracil using therapeutic drug monitoring (PREDICT-5FU): A multicentre clinical trial.

Sarah Glewis, Michael Michael, Howard Gurney

|Nov 29, 2024
Pharmacogenetic-guided dosing for fluoropyrimidine (DPYD) and irinotecan (UGT1A1*28) chemotherapies for patients with cancer (PACIFIC-PGx): A multicenter clinical trial.

Sarah Glewis, Senthil Lingaratnam, Benjamin Lee

|Oct 25, 2023
Patient and healthcare professional acceptability of pharmacogenetic screening for DPYD and UGT1A1: A cross sectional survey.

Sarah Glewis, Mei Krishnasamy, Senthil Lingaratnam

Pageof 2

Frequent Collaborators

6 joint publications

Marliese Alexander

2 joint publications

Senthil Lingaratnam

2 joint publications

Craig Underhill

1 joint publications

Jeanne Tie